Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis

Diabetes Research and Clinical Practice

Volumn 79, Issue 2, 2008, Pages 196-203

  Monami, Matteo ^a   Lamanna, Caterina ^a   Marchionni, Niccolò ^a   Mannucci, Edoardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Meta analysis; Metformin; Oral hyperglycemic drugs

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPRIDE; GLINIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; UNCLASSIFIED DRUG;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTEMATIC REVIEW; TREATMENT FAILURE;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PATIENT SELECTION; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 38349121004     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.08.024     Document Type: Article

References (51)

1. International Diabetes Federation: Global Guidelines for type 2 diabetes. (Article on line) (2005).
2. Nathan D.M. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American diabetes association and the European association for the study of diabetes: response to cryer, porta and trento, and parkin and davidson. Diabetes Care 30 (2007) 194-196
3. Matthews D.R., Cull C.A., Stratton I.M., Holman R.R., and Turner R.C. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet. Med. 15 (1998) 297-303
4. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355 (2006) 2427-2443
5. DeFronzo R.A., and Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N. Engl. J. Med. 333 (1995) 541-549
6. Hedges L., and Olkin I. Methods for Meta-Analysis (1985), Academic Press, New York
7. Phillips P., Karrasch J., Scott R., Wilson D., and Moses R. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 26 (2003) 269-273
8. Rosenstock J., Brown A., Fischer J., Jain A., Littlejohn T., Nadeau D., et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 21 (1998) 2050-2055
9. Halimi S., Le Berre M.A., and Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res. Clin. Pract. 50 (2000) 49-56
10. Josse R.G. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial. Diabetes Res. Clin. Pract. 28 Suppl. (1995) S167-S172
11. Van G.L., Maislos M., Schernthaner G., Rybka J., and Segal P. Miglitol combined with metformin improves glycaemic control in type 2 diabetes. Diabetes Obes. Metab. 3 (2001) 326-331
12. Feinglos M., Dailey G., Cefalu W., Osei K., Tayek J., Canovatchel W., et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res. Clin. Pract. 68 (2005) 167-175
13. Marre M., Howlett H., Lehert P., and Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet. Med. 19 (2002) 673-680
14. Gomez-Perez F.J., Fanghanel-Salmon G., Antonio B.J., Montes-Villarreal J., Berry R.A., Warsi G., et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab. Res. Rev. 18 (2002) 127-134
15. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
16. Charpentier G., Fleury F., Kabir M., Vaur L., and Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet. Med. 18 (2001) 828-834
17. Goldstein B.J., Pans M., and Rubin C.J. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin. Ther. 25 (2003) 890-903
18. Blonde L., Rosenstock J., Mooradian A.D., Piper B.A., and Henry D. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes. Metab. 4 (2002) 368-375
19. Moses R. Repaglinide in combination therapy with metformin in Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 107 Suppl. 4 (1999) S136-S139
20. Marre M., Van G.L., Usadel K.H., Ball M., Whatmough I., and Guitard C. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes. Metab. 4 (2002) 177-186
21. Einhorn D., Rendell M., Rosenzweig J., Egan J.W., Mathisen A.L., and Schneider R.L. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin. Ther. 22 (2000) 1395-1409
22. Bailey C.J., Bagdonas A., Rubes J., McMorn S.O., Donaldson J., Biswas N., et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin. Ther. 27 (2005) 1548-1561
23. Schernthaner G., Grimaldi A., Di M.U., Drzewoski J., Kempler P., Kvapil M., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur. J. Clin. Invest. 34 (2004) 535-542
24. Raskin P., Klaff L., McGill J., South S.A., Hollander P., Khutoryansky N., et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 26 (2003) 2063-2068
25. Garber A., Klein E., Bruce S., Sankoh S., and Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes. Metab. 8 (2006) 156-163
26. Umpierrez G., Issa M., and Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr. Med. Res. Opin. 22 (2006) 751-759
27. Matthews D.R., Charbonnel B.H., Hanefeld M., Brunetti P., and Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab. Res. Rev. 21 (2005) 167-174
28. Derosa G., Cicero A.F., Gaddi A.V., Ciccarelli L., Piccinni M.N., Salvadeo S., et al. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin. Ther. 27 (2005) 1383-1391
29. Kvapil M., Swatko A., Hilberg C., and Shestakova M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes. Metab. 8 (2006) 39-48
30. Malone J.K., Beattie S.D., Campaigne B.N., Johnson P.A., Howard A.S., and Milicevic Z. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?. Diabetes Res. Clin. Pract. 62 (2003) 187-195
31. Malone J.K., Kerr L.F., Campaigne B.N., Sachson R.A., and Holcombe J.H. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin. Ther. 26 (2004) 2034-2044
32. Raskin P., Allen E., Hollander P., Lewin A., Gabbay R.A., Hu P., et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
33. Kendall D., Rubin C., Mohideen P., Ledeine J., Belder R., Gross J., et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29 (2006) 1016-1023
34. Derosa G., Gaddi A.V., Piccinni M.N., Salvadeo S., Ciccarelli L., Fogari E., et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomised, double-blind, clinical trial. Diabetes Obes. Metab. 8 (2006) 197-205
35. Van de Laar F.A., Lucassen P.L., Akkermans R.P., Van de Lisdonk E.H., Rutten G.E., and Van W.C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane. Database. Syst. Rev. (2005) CD003639
36. Groop L.C. Sulfonylureas in NIDDM. Diabetes Care 15 (1992) 737-754
37. Genuth S. Insulin use in NIDDM. Diabetes Care 13 (1990) 1240-1264
38. Bailey C.J., and Turner R.C. Metformin. N. Engl. J. Med. 334 (1996) 574-579
39. Hoffmann J., and Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am. J. Med. 103 (1997) 483-490
40. Spengler M., Hansel G., and Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor Acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM). Horm. Metab. Res. Suppl. 26 (1992) 50-51
41. Rosenstock J., Hassman D.R., Madder R.D., Brazinsky S.A., Farrell J., Khutoryansky N., et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27 (2004) 1265-1270
42. Gerich J., Raskin P., Jean-Louis L., Purkayastha D., and Baron M.A. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28 (2005) 2093-2099
43. Tan M., Johns D., Strand J., Halse J., Madsbad S., Eriksson J., et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet. Med. 21 (2004) 859-866
44. St John S., Rendell M., Dandona P., Dole J., Murphy K., Patwardhan R., et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 25 (2002) 2058-2064
45. Stehouwer M.H., DeVries J.H., Lumeij J.A., Ader H.J., Engbers A.M., Iperen A.A., et al. Combined bedtime insulin-daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate-a randomised trial. Diabetes Metab. Res. Rev. 19 (2003) 148-152
46. Goudswaard A.N., Stolk R.P., Zuithoff P., de Valk H.W., and Rutten G.E. Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. J. Fam. Pract. 53 (2004) 393-399
47. Christiansen J.S., Vaz J.A., Metelko Z., Bogoev M., and Dedov I. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes. Metab. 5 (2003) 446-454
48. Janka H.U., Plewe G., Riddle M.C., Kliebe-Frisch C., Schweitzer M.A., and Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28 (2005) 254-259
49. Ross S.A., Zinman B., Campos R.V., and Strack T. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin. Invest. Med. 24 (2001) 292-298
50. Coscelli C., Iacobellis G., Calderini C., Carleo R., Gobbo M., Di M.U., et al. Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. Acta Diabetol. 40 (2003) 187-192
51. McSorley P.T., Bell P.M., Jacobsen L.V., Kristensen A., and Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin. Ther. 24 (2002) 530-539